{"id":11170,"date":"2026-07-06T14:04:53","date_gmt":"2026-07-06T12:04:53","guid":{"rendered":"https:\/\/www.iqac.csic.es\/proyecto\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/"},"modified":"2026-07-06T14:04:53","modified_gmt":"2026-07-06T12:04:53","slug":"avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma","status":"publish","type":"proyecto","link":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/","title":{"rendered":"Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma"},"content":{"rendered":"<p>Els c\u00e0ncers de mama agressius solen resistir les ter\u00e0pies est\u00e0ndard a causa de mecanismes relacionats tant amb les c\u00e8l\u00b7lules tumorals com amb el microambient tumoral. Molts f\u00e0rmacs quimioterap\u00e8utics augmenten les ceramides, l\u00edpids que afavoreixen la mort cel\u00b7lular. La CERT, una prote\u00efna implicada en el transport de ceramides, en redueix l&#8217;acumulaci\u00f3; per aix\u00f2, disminuir els nivells de CERT podria augmentar la sensibilitat a la quimioter\u00e0pia en incrementar els valors de les ceramides i millorar la resposta terap\u00e8utica. Aquest projecte investiga el paper de la CERT en la resist\u00e8ncia al tractament i desenvolupa nous degradadors capa\u00e7os de dirigir la CERT directament al proteasoma a trav\u00e9s d&#8217;Usp14, sense dependre de lligases E3. Les mol\u00e8cules desenvolupades s&#8217;han validat mitjan\u00e7ant s\u00edntesi qu\u00edmica, caracteritzaci\u00f3 bioqu\u00edmica i estudis en models de c\u00e0ncer de mama, aportant evid\u00e8ncies que la CERT \u00e9s una prometedora diana terap\u00e8utica.    <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aquest projecte investiga com la prote\u00efna CERT contribueix a la resist\u00e8ncia a la quimioter\u00e0pia en el c\u00e0ncer de mama agressiu, incloent-hi les interaccions amb els fibroblasts associats al c\u00e0ncer (CAFs), i explora si la reducci\u00f3 de CERT pot millorar la resposta al tractament. Per aconseguir-ho, els investigadors han desenvolupat noves mol\u00e8cules basades en PROTACs que degraden directament CERT a trav\u00e9s del proteasoma, amb l&#8217;objectiu de potenciar la mort de les c\u00e8l\u00b7lules canceroses i validar CERT com una diana terap\u00e8utica. <\/p>\n","protected":false},"featured_media":11171,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[170,207],"enfermedad":[167],"framework":[131],"linea-de-investigacion":[184,168],"class_list":["post-11170","proyecto","type-proyecto","status-publish","has-post-thumbnail","hentry","tag-descobriment-de-farmacs","tag-proteines","enfermedad-cancer","framework-plan-estatal-peicti","linea-de-investigacion-comprendre","linea-de-investigacion-tractar","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"og:description\" content=\"Aquest projecte investiga com la prote\u00efna CERT contribueix a la resist\u00e8ncia a la quimioter\u00e0pia en el c\u00e0ncer de mama agressiu, incloent-hi les interaccions amb els fibroblasts associats al c\u00e0ncer (CAFs), i explora si la reducci\u00f3 de CERT pot millorar la resposta al tractament. Per aconseguir-ho, els investigadors han desenvolupat noves mol\u00e8cules basades en PROTACs que degraden directament CERT a trav\u00e9s del proteasoma, amb l&#039;objectiu de potenciar la mort de les c\u00e8l\u00b7lules canceroses i validar CERT com una diana terap\u00e8utica.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/\" \/>\n<meta property=\"og:site_name\" content=\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/iqac.csic.es\/\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/certacs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"1125\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@IQAC_CSIC\" \/>\n<meta name=\"twitter:label1\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\\\/\",\"name\":\"Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/certacs.jpg\",\"datePublished\":\"2026-07-06T12:04:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/certacs.jpg\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/certacs.jpg\",\"width\":2000,\"height\":1125,\"caption\":\"Mujer realizando un gesto de silencio para representar silenciadores qu\u00edmicos dirigidos al proteasoma en la investigaci\u00f3n del c\u00e1ncer de mama.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/projecte\\\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.iqac.csic.es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"description\":\"Chemistry for a better life\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\"},\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.iqac.csic.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"width\":512,\"height\":512,\"caption\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/iqac.csic.es\\\/\",\"https:\\\/\\\/x.com\\\/IQAC_CSIC\",\"https:\\\/\\\/www.instagram.com\\\/iqac_csic\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC1JXTOe3-s8UnYu_A6-SI3A\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/iqac-csic\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/","og_locale":"ca_ES","og_type":"article","og_title":"Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","og_description":"Aquest projecte investiga com la prote\u00efna CERT contribueix a la resist\u00e8ncia a la quimioter\u00e0pia en el c\u00e0ncer de mama agressiu, incloent-hi les interaccions amb els fibroblasts associats al c\u00e0ncer (CAFs), i explora si la reducci\u00f3 de CERT pot millorar la resposta al tractament. Per aconseguir-ho, els investigadors han desenvolupat noves mol\u00e8cules basades en PROTACs que degraden directament CERT a trav\u00e9s del proteasoma, amb l'objectiu de potenciar la mort de les c\u00e8l\u00b7lules canceroses i validar CERT com una diana terap\u00e8utica.","og_url":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/","og_site_name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","article_publisher":"https:\/\/www.facebook.com\/iqac.csic.es\/","og_image":[{"width":2000,"height":1125,"url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/certacs.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@IQAC_CSIC","twitter_misc":{"Temps estimat de lectura":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/","url":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/","name":"Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","isPartOf":{"@id":"https:\/\/www.iqac.csic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/#primaryimage"},"image":{"@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/certacs.jpg","datePublished":"2026-07-06T12:04:53+00:00","breadcrumb":{"@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/#primaryimage","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/certacs.jpg","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/07\/certacs.jpg","width":2000,"height":1125,"caption":"Mujer realizando un gesto de silencio para representar silenciadores qu\u00edmicos dirigidos al proteasoma en la investigaci\u00f3n del c\u00e1ncer de mama."},{"@type":"BreadcrumbList","@id":"https:\/\/www.iqac.csic.es\/ca\/projecte\/avaluacio-del-paper-de-la-cert-en-el-cancer-de-mama-mitjancant-silenciadors-quimics-innovadors-dirigits-al-proteasoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.iqac.csic.es\/"},{"@type":"ListItem","position":2,"name":"Avaluaci\u00f3 del paper de la CERT en el c\u00e0ncer de mama mitjan\u00e7ant silenciadors qu\u00edmics innovadors dirigits al proteasoma"}]},{"@type":"WebSite","@id":"https:\/\/www.iqac.csic.es\/#website","url":"https:\/\/www.iqac.csic.es\/","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","description":"Chemistry for a better life","publisher":{"@id":"https:\/\/www.iqac.csic.es\/#organization"},"alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.iqac.csic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.iqac.csic.es\/#organization","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","url":"https:\/\/www.iqac.csic.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","width":512,"height":512,"caption":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC"},"image":{"@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/iqac.csic.es\/","https:\/\/x.com\/IQAC_CSIC","https:\/\/www.instagram.com\/iqac_csic","https:\/\/www.youtube.com\/channel\/UC1JXTOe3-s8UnYu_A6-SI3A","https:\/\/www.linkedin.com\/company\/iqac-csic\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/proyecto\/11170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/proyecto"}],"about":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/types\/proyecto"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/media\/11171"}],"wp:attachment":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/media?parent=11170"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/tags?post=11170"},{"taxonomy":"enfermedad","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/enfermedad?post=11170"},{"taxonomy":"framework","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/framework?post=11170"},{"taxonomy":"linea-de-investigacion","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/linea-de-investigacion?post=11170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}